NCT03169738 2025-02-21
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
ImmunityBio, Inc.
Phase 1/2 Withdrawn
Clinical Trials
12 trialsNCT04151563 2023-12-19
CheckMate 79X
Bristol-Myers Squibb
Phase 1/2 Withdrawn
NCT05022394 2022-05-27
Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT03770299 2022-03-24
CheckMate 9TN
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT04758949 2022-01-11
FL-101 in Surgically Resectable Non-Small Cell Lung Cancer
Flame Biosciences
Phase 2 Withdrawn
NCT02466568 2019-09-09
Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Withdrawn
NCT03417037 2018-04-30
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT03023904 2018-04-25
Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT03048136 2018-04-17
CheckMate 955
Bristol-Myers Squibb
Phase 3 Withdrawn
NCT02924233 2017-08-28
Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
Symphogen A/S
Phase 1/2 Withdrawn
NCT02639234 2017-07-31
Vigilâ„¢ + Nivolumab in Advanced Non-Small Cell Lung Cancer
Gradalis, Inc.
Phase 2 Withdrawn
NCT02950038 2017-02-13
Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 2 Withdrawn